FY2022 EPS Estimates for Health Catalyst, Inc. (NASDAQ:HCAT) Increased by Analyst

Health Catalyst, Inc. (NASDAQ:HCATGet Rating) – Stock analysts at Jefferies Financial Group lifted their FY2022 earnings estimates for Health Catalyst in a research report issued on Tuesday, November 15th. Jefferies Financial Group analyst G. Santangelo now forecasts that the company will post earnings per share of ($1.54) for the year, up from their previous forecast of ($1.64). The consensus estimate for Health Catalyst’s current full-year earnings is ($1.67) per share. Jefferies Financial Group also issued estimates for Health Catalyst’s Q4 2022 earnings at ($0.33) EPS and FY2023 earnings at ($1.46) EPS.

HCAT has been the subject of several other reports. Stifel Nicolaus lowered shares of Health Catalyst from a “buy” rating to a “hold” rating and lowered their target price for the company from $27.00 to $16.00 in a report on Friday, August 5th. The Goldman Sachs Group lowered their target price on shares of Health Catalyst from $29.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. BTIG Research lowered their target price on shares of Health Catalyst to $17.00 in a report on Tuesday. Royal Bank of Canada lowered shares of Health Catalyst from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $19.00 to $9.00 in a report on Tuesday, October 25th. Finally, Wells Fargo & Company started coverage on shares of Health Catalyst in a report on Monday, October 31st. They set an “equal weight” rating and a $10.00 target price for the company. Six investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average price target of $18.53.

Health Catalyst Stock Performance

Shares of HCAT opened at $9.79 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.87 and a quick ratio of 4.87. Health Catalyst has a one year low of $6.40 and a one year high of $50.00. The company has a 50-day simple moving average of $9.44 and a two-hundred day simple moving average of $12.57. The firm has a market capitalization of $536.01 million, a PE ratio of -3.33 and a beta of 1.18.

Health Catalyst (NASDAQ:HCATGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.08. Health Catalyst had a negative net margin of 55.42% and a negative return on equity of 19.05%. The business had revenue of $68.35 million during the quarter, compared to analyst estimates of $66.85 million.

Insiders Place Their Bets

In related news, CEO Daniel D. Burton bought 197,078 shares of the business’s stock in a transaction on Friday, November 11th. The stock was acquired at an average price of $10.14 per share, with a total value of $1,998,370.92. Following the transaction, the chief executive officer now owns 900,140 shares in the company, valued at approximately $9,127,419.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Health Catalyst

Hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP grew its position in shares of Health Catalyst by 128.9% during the 1st quarter. Engineers Gate Manager LP now owns 117,471 shares of the company’s stock valued at $3,070,000 after acquiring an additional 66,141 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Health Catalyst by 870.7% during the 1st quarter. Qube Research & Technologies Ltd now owns 51,486 shares of the company’s stock valued at $1,345,000 after acquiring an additional 46,182 shares during the period. Madison Asset Management LLC bought a new stake in shares of Health Catalyst during the 1st quarter valued at $2,069,000. Parkman Healthcare Partners LLC grew its position in shares of Health Catalyst by 51.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 79,746 shares of the company’s stock valued at $2,084,000 after acquiring an additional 27,068 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Health Catalyst by 1,339.6% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 160,124 shares of the company’s stock valued at $2,320,000 after acquiring an additional 149,001 shares during the period. Institutional investors own 96.58% of the company’s stock.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Featured Stories

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.